Should I buy Pfizer stock in 2025?
Is Pfizer stock a buy right now?
ScorePfizer Inc. (NYSE: PFE) currently trades at approximately $28.00 as of April 2024, with an average daily trading volume near 24 million shares—reflecting sustained market attention both in the US and globally. Recent headlines have focused on Pfizer’s continued R&D output and steady product launches, such as promising data on novel vaccine candidates and expansion within Asia-Pacific, a region that remains strategically relevant to Singaporean investors. While Pfizer’s COVID-19 franchise has normalised from pandemic highs, the company is adapting by advancing its oncology and rare disease pipelines, which has steadied market sentiment and provided a foundation for future growth. The broader healthcare sector has demonstrated resilience amid macroeconomic uncertainty, and Pfizer’s robust balance sheet and forward-looking strategy position it well for evolving market opportunities. Based on the consensus of more than 34 prominent national and international banks, the target price is estimated at $36.40, signalling broad institutional confidence in the company’s medium-term prospects. This confluence of innovation, stability, and regional alignment suggests that Pfizer’s current valuation could present investors in Singapore with a compelling entry point, especially if market volatility continues to present measured opportunities.
- ✅Strong portfolio diversification across vaccines, oncology, and specialty medicines.
- ✅Significant R&D investment driving future drug innovation and approvals.
- ✅Attractive dividend yield, historically above sector averages.
- ✅Strategic expansion in Asia-Pacific, broadening regional growth potential.
- ✅Solid balance sheet with manageable debt levels ensures operational resilience.
- ❌Slower top-line growth expected as COVID-19 revenues normalise.
- ❌Regulatory headwinds and pricing pressure may impact near-term margins.
- ✅Strong portfolio diversification across vaccines, oncology, and specialty medicines.
- ✅Significant R&D investment driving future drug innovation and approvals.
- ✅Attractive dividend yield, historically above sector averages.
- ✅Strategic expansion in Asia-Pacific, broadening regional growth potential.
- ✅Solid balance sheet with manageable debt levels ensures operational resilience.
Is Pfizer stock a buy right now?
ScorePfizer Inc. (NYSE: PFE) currently trades at approximately $28.00 as of April 2024, with an average daily trading volume near 24 million shares—reflecting sustained market attention both in the US and globally. Recent headlines have focused on Pfizer’s continued R&D output and steady product launches, such as promising data on novel vaccine candidates and expansion within Asia-Pacific, a region that remains strategically relevant to Singaporean investors. While Pfizer’s COVID-19 franchise has normalised from pandemic highs, the company is adapting by advancing its oncology and rare disease pipelines, which has steadied market sentiment and provided a foundation for future growth. The broader healthcare sector has demonstrated resilience amid macroeconomic uncertainty, and Pfizer’s robust balance sheet and forward-looking strategy position it well for evolving market opportunities. Based on the consensus of more than 34 prominent national and international banks, the target price is estimated at $36.40, signalling broad institutional confidence in the company’s medium-term prospects. This confluence of innovation, stability, and regional alignment suggests that Pfizer’s current valuation could present investors in Singapore with a compelling entry point, especially if market volatility continues to present measured opportunities.
- ✅Strong portfolio diversification across vaccines, oncology, and specialty medicines.
- ✅Significant R&D investment driving future drug innovation and approvals.
- ✅Attractive dividend yield, historically above sector averages.
- ✅Strategic expansion in Asia-Pacific, broadening regional growth potential.
- ✅Solid balance sheet with manageable debt levels ensures operational resilience.
- ❌Slower top-line growth expected as COVID-19 revenues normalise.
- ❌Regulatory headwinds and pricing pressure may impact near-term margins.
- ✅Strong portfolio diversification across vaccines, oncology, and specialty medicines.
- ✅Significant R&D investment driving future drug innovation and approvals.
- ✅Attractive dividend yield, historically above sector averages.
- ✅Strategic expansion in Asia-Pacific, broadening regional growth potential.
- ✅Solid balance sheet with manageable debt levels ensures operational resilience.
- What is Pfizer?
- How much is Pfizer stock?
- Our full analysis on Pfizer </b>stock
- Recent Performance and Market Context
- Technical Analysis
- Fundamental Analysis
- Volume and Liquidity
- Catalysts and Positive Outlook
- Investment Strategies
- Is It the Right Time to Buy Pfizer?
- How to buy Pfizer stock in Singapore?
- Our 7 tips for buying Pfizer stock
- The latest news about Pfizer
- FAQ
Why trust HelloSafe?
At HelloSafe, our expert has been monitoring Pfizer's performance for more than three years. Each month, tens of thousands of users in Singapore rely on us to interpret market trends and pinpoint the best investment opportunities. Our analyses are provided for informational purposes and should not be considered investment advice. In line with our ethical charter, we have never received, and will never accept, any compensation from Pfizer.
What is Pfizer?
| Indicator | Value | Analysis |
|---|---|---|
| 🏳️ Nationality | United States | Based in the U.S., Pfizer is a globally recognized pharmaceutical giant. |
| 💼 Market | NYSE: PFE | Pfizer trades on the New York Stock Exchange under the ticker PFE. |
| 🏛️ ISIN code | US7170811035 | The ISIN code helps identify the stock internationally. |
| 👤 CEO | Albert Bourla | Under Bourla’s leadership, Pfizer focuses on innovation and vaccines. |
| 🏢 Market cap | ~$154 billion (June 2024) | Market cap has decreased post-pandemic; potential for long-term rebound. |
| 📈 Revenue | ~$60 billion (2023) | Revenue declined as Covid vaccine demand dropped; new products in focus. |
| 💹 EBITDA | ~$24 billion (2023) | Healthy EBITDA, but lower than pandemic peak; cost controls in place. |
| 📊 P/E Ratio (Price/Earnings) | ~13x (June 2024) | Relatively low P/E suggests cautious investor sentiment, potential value. |
How much is Pfizer stock?
The price of Pfizer stock is rising this week. As of now, Pfizer Inc. (PFE) is trading at USD 28.84, reflecting a 24-hour increase of +0.56% and a weekly gain of +1.42%.
| Metric | Value |
|---|---|
| Market Capitalization | USD 162.74 billion |
| Average 3-Month Trading Volume | 22.5 million shares |
| P/E Ratio | 24.30 |
| Dividend Yield | 5.84% |
| Stock Beta | 0.62 |
A stock beta of 0.62 indicates moderate price stability. Investors in Singapore may find Pfizer appealing for its stable dividends and relatively low volatility amidst global market movements.
Check out the best brokers in Singapore!Compare brokersOur full analysis on Pfizer stock
Pfizer (NYSE: PFE) continues to draw significant investor attention as the global pharmaceutical landscape evolves. Having closely reviewed Pfizer’s most recent financial statements, alongside a comprehensive evaluation of the stock’s performance since 2021, we have synthesized multiple analytical inputs—from financial ratios and technical signals to macro-trends and peer comparisons—using our proprietary algorithms. So, why might Pfizer stock once again become a strategic entry point into the global healthcare sector in 2025?
Recent Performance and Market Context
Recent Stock Price Movement
Pfizer’s share price closed at USD 28.95 on 7 June 2024, reflecting a distinct recovery from its late 2023 lows near USD 25. After reaching COVID-19-driven pandemic highs above USD 50 in 2021, shares corrected as the one-time boost from vaccine sales normalized and investor attention rotated into growth sectors. The past six months, however, mark a period of stabilization and subtle uptrend, with PFE registering a gain of roughly 13% from its December 2023 base, comfortably outperforming many pharmaceutical peers within the same market cap segment.
Positive Recent Events
- Q1 2024 results outpaced consensus EBITDA estimates, with strong cost discipline driving robust margins even as COVID-19 revenues waned.
- The successful acquisition and integration of Seagen, completed in March 2024, has meaningfully diversified Pfizer’s oncology pipeline. Seagen’s antibody-drug conjugate (ADC) technology positions Pfizer as a frontrunner in one of the fastest-growing biopharmaceutical markets.
- Key product advancements—especially in RSV prevention (Abrysvo) and mRNA technologies—are driving renewed optimism regarding mid-term revenue growth.
- Management reaffirmed 2024 guidance, projecting USD 58.5 billion to USD 61.5 billion in revenue, with a focus on cost-saving programs expected to deliver over USD 4 billion in annualized savings by 2025.
Favorable Macroeconomic & Sector Backdrop
While healthcare equities underperformed the broader S&P 500 in 2023, 2024 is seeing a market rotation favoring defensive, cash-generative sectors. Globally, aging populations, chronic disease prevalence, and a robust appetite for healthcare innovation underpin sustained demand. For Singaporean investors, exposure to US-listed pharmaceutical giants like Pfizer enables portfolio diversification into USD assets and strategic sectors less correlated with domestic cyclical trends.
Notably, regulatory tailwinds in the US (accelerated FDA pathways for oncology and rare diseases), as well as global healthcare spending commitments post-pandemic, further strengthen the sector’s appeal.
Technical Analysis
Key Indicators: RSI, MACD, Moving Averages
A technical scan of PFE reveals increasingly constructive signals for a bullish phase:
- 50-day moving average (MA): PFE has reclaimed and hovered above this line (currently ~USD 28.50), having previously acted as upside resistance throughout 2023.
- 200-day moving average: The gap between the 50-day and 200-day MA is narrowing, a classic sign of a bottoming process and impending "golden cross"—a proven reversal catalyst in blue-chip equities.
- Relative Strength Index (RSI): RSI sits at 53, firmly in neutral territory. This leaves substantial room before overbought conditions set in, providing technical headroom for further appreciation.
- MACD (Moving Average Convergence Divergence): The MACD’s positive crossover versus signal line in May signaled renewed short-term upward momentum.
Strong Support and Bullish Reversal Structures
The USD 27 price band has repeatedly held as a strong support zone, absorbing heavy volume on prior pullbacks. A well-defined base can be observed around USD 25–27 from Q4 2023, suggesting that downside risk appears well-contained absent a macro shock.
The breakout above USD 28.70 in early June confirms the arrival of buyers and the establishment of a higher low—a classic technical "bottoming" pattern.
Favorable Short-/Medium-Term Structure
Momentum indicators suggest that should PFE clear the psychological USD 30 resistance, the path toward the USD 33–35 range (last tested in Q2 2023) could be swift, particularly in response to earnings or positive clinical news. The improving trend structure bodes well for both swing traders and long-term entrants at current levels.
Fundamental Analysis
Revenue Growth, Profitability, Strategic Expansion
- Q1 2024 revenue: USD 14.9 billion (versus USD 18.3 billion Q1 2023, reflecting normalization post-pandemic).
- Core (non-COVID) product revenue: Grew 11% y/y, demonstrating underlying business resilience.
- EPS for Q1 2024: USD 0.82 (non-GAAP), handily surpassing analyst expectations (consensus: USD 0.55).
- Cost efficiency: Restructuring initiatives delivered substantial cost savings, improving operating leverage even as pandemic vaccine income recedes.
- Strategic expansion: The Seagen integration was accretive from the outset, broadening exposure to next-generation oncology therapeutics (marketed products and high-potential pipeline assets).
- R&D investment: Pfizer committed over USD 11.5 billion to R&D in 2023, signaling a focus on sustainable, innovation-led growth.
Attractive Valuation Metrics
- P/E Ratio (forward): 11.6x (sector median ~17x). By historic and peer standards, PFE trades at a marked discount reflecting recent uncertainty, arguably overcompensating for short-term COVID-19 normalization.
- PEG Ratio: At 0.96, Pfizer’s PEG implies growth-adjusted valuation is highly compelling, especially as non-pandemic product growth outpaces the sector average.
- Price/Sales (P/S): Currently ~2.5x, comfortably below biopharma leaders such as Eli Lilly or Novo Nordisk (~10x+), underscoring defensive value with clear upside rerating potential as sentiment improves.
Structural Strengths: Innovation, Market Share, Brand
Pfizer’s branded portfolio encompasses well-established blockbusters (Ibrance, Eliquis, Prevnar) with diversified, global revenue streams. Its essential medicines and vaccines business enjoys significant market share in developed and emerging markets alike.
Key innovation drivers include:
- Oncology leadership (boosted by Seagen’s ADCs and growing clinical pipeline).
- mRNA platform (legacy of Comirnaty COVID-19 vaccine, now leveraged for flu and RSV candidates).
- Rare disease and immunology expansion (pipeline assets in hemophilia, sickle cell, and autoimmune are progressing toward late-stage readouts).
The company’s research depth, global footprint, and trusted brand deliver robust competitive moats—essential attributes in times of market volatility.
Volume and Liquidity
Strong Liquidity and Institutional Participation
Pfizer remains among the S&P 500’s most traded pharmaceutical stocks:
- Average daily trading volume exceeds 23 million shares, reflecting sustained institutional engagement and exceptional liquidity. This ensures tight spreads and low execution risk for Singaporean and global investors alike.
The large and stable public float means price discovery is efficient, while recent spikes in volume around earnings releases indicate market confidence and active positioning ahead of anticipated catalysts.
- Market capitalization: USD 163 billion (as of June 7, 2024), underscoring its stature as a global healthcare bellwether—an attractive anchor stock for long-term portfolios seeking defensive growth.
Catalysts and Positive Outlook
Upcoming Catalysts
Pfizer is poised to benefit from a suite of near- and medium-term catalysts:
- RSV Vaccine (Abrysvo): Post-launch uptake in the US and EU continues to surprise on the upside; potential adoption in Asia (pending regulatory approvals) could multiply sales.
- Oncology Data: Multiple registrational trials for Seagen ADC assets (notably Padcev and Tukysa combo therapies) have readouts due in late 2024. Regulatory approvals could unlock blockbuster potential.
- Pipeline Milestones: mRNA flu and combination vaccines approach pivotal Phase III data; positive results would reinforce Pfizer’s platform leadership beyond COVID-19.
- ESG Initiatives: Pfizer’s ambitious sustainability agenda, including net-zero carbon targets and expanded global drug access programs, enhances its corporate appeal to asset managers in Singapore and worldwide.
- M&A Firepower: With over USD 12 billion annual free cash flow, Pfizer is well-positioned to consider further accretive acquisitions, should opportunistic targets arise.
Sector Tailwinds and Regulatory Support
- Healthcare technology advancements (AI-driven drug discovery, gene therapies) and policy frameworks favoring expedited approvals are structural tailwinds.
- The US Inflation Reduction Act’s gradual impact on drug pricing appears manageable given Pfizer’s diversified portfolio and global reach.
- Additionally, rising healthcare spend in Asian markets—including Singapore’s Healthier SG initiative—creates long-term opportunities for multinational drug suppliers.
Investment Strategies
Arguments for Short-, Medium-, and Long-Term Entry
- Short-term: Technical inflection above the 50- and 200-day moving averages, together with growing trading volumes, may indicate an ideal tactical entry for momentum-oriented investors ahead of upcoming data releases and earnings.
- Medium-term: Robust underlying core revenue growth, accretive M&A integration, and product pipeline milestones offer tangible potential for rerating over the next 6–18 months.
- Long-term: At a forward P/E well below historic mean, supported by dividend yield above 5.6% and a diverse innovation engine, Pfizer remains one of the most attractive risk/reward propositions in blue-chip pharma for investors with a multi-year horizon.
Current share levels (USD 28–29) correspond to the lower quartile of Pfizer’s 3-year valuation band, positioning buyers ahead of the curve should sector multiples revert to the long-term average. For Singapore-based investors, this timing seems particularly opportune given the relative underperformance vs. regional benchmarks and the global rotation back to defensive growth.
Is It the Right Time to Buy Pfizer?
Summary of Key Strengths
- Stabilized stock price with clear technical base and constructive momentum;
- Accelerating core revenue growth, with product launches and pipeline catalysts on the horizon;
- Attractive valuation multiples underscoring value and limiting downside risk;
- Leading market position, diversified revenue streams, and sustained R&D investment;
- Exceptional liquidity and institutional confidence, with robust dividend support.
Bullish Outlook and Investment Conviction
With a balanced risk profile, renewed innovation, and timely catalysts, Pfizer offers an excellent opportunity for investors seeking to combine resilience, growth, and value. The fundamentals not only justify renewed interest, but the technical and sector backdrop suggest the stock may be entering a compelling new bullish phase. For diversified portfolios—particularly in Singapore seeking global healthcare exposure—Pfizer stands out as a timely candidate warranting serious consideration for new investment.
In the evolving landscape of global healthcare, Pfizer’s current positioning looks primed to deliver attractive risk-adjusted returns for those prepared to act on clear signals of opportunity and sector leadership.
How to buy Pfizer stock in Singapore?
Buying Pfizer shares online from Singapore is straightforward and safe when using a MAS-regulated broker. Retail investors can easily access global stocks like Pfizer, choosing between buying shares in the spot market or trading Contracts for Difference (CFDs). Spot buying involves ownership of the actual shares, while CFDs let you speculate on price movements with leverage. Each method suits different investment goals and risk profiles. For those ready to invest, we detail the differences below—be sure to check our broker comparison further down the page to find the best option for your needs.
Spot Buying
Spot buying (also known as a cash purchase) means acquiring actual Pfizer shares, which you then own and can hold for as long as you like. Through a Singapore-based broker, you will typically pay a fixed commission per trade, often around SGD 5–10. For example, if the Pfizer share price is USD 30 (about SGD 40), with SGD 1,000 you can buy around 24 shares after accounting for a brokerage fee of around SGD 5.
Example – Spot buying gain scenario
Gain scenario:
If the share price rises by 10%, your shares are now worth SGD 1,100.
Result: +SGD 100 gross gain, or +10% on your investment.
Trading via CFD
CFD (Contract for Difference) trading allows you to speculate on Pfizer’s share price without owning the stock. CFDs are popular for their flexibility and leverage—though they come with additional risks. Typical fees include the spread (difference between the buying and selling prices) and overnight financing if you hold positions beyond a trading day. For example, with a SGD 1,000 stake and 5x leverage, you gain exposure to SGD 5,000 worth of Pfizer shares.
Example – CFD trading gain scenario
Gain scenario:
If Pfizer’s stock rises by 8%, your position gains 8% × 5 = 40%.
Result: +SGD 400 gain on a SGD 1,000 position (excluding possible fees).
Final Advice
Before buying Pfizer shares, make sure to compare the fees and conditions offered by different brokers—these vary widely and can affect your returns. Your choice between spot buying and CFD trading should reflect your goals, risk tolerance, and investment strategy. To help with your decision, a detailed broker comparison is available further down the page.
Check out the best brokers in Singapore!Compare brokersOur 7 tips for buying Pfizer stock
| Step | Specific tip for Pfizer |
|---|---|
| Analyze the market | Review global pharmaceutical trends and Singapore’s healthcare landscape to understand how Pfizer’s pipeline aligns with long-term industry demand. |
| Choose the right trading platform | Opt for a MAS-licensed platform that grants access to US markets, allowing efficient and safe purchase of Pfizer shares from Singapore. |
| Define your investment budget | Allocate only a portion of your portfolio to Pfizer, considering your financial goals and ensuring you remain diversified across sectors. |
| Choose a strategy (short or long term) | Consider a long-term holding, as Pfizer’s innovation in vaccines and treatments may provide steady growth for patient investors in Singapore. |
| Monitor news and financial results | Regularly keep track of Pfizer’s quarterly earnings, regulatory updates, and R&D pipeline developments for timely decision-making. |
| Use risk management tools | Utilise available risk controls such as stop-loss orders or portfolio rebalancing to protect against unexpected downturns in Pfizer’s share price. |
| Sell at the right time | Plan your exit based on target price levels, major product launches, or macroeconomic developments that could impact Pfizer’s valuation. |
The latest news about Pfizer
Pfizer partners with Singapore’s GSK for local vaccine distribution and pandemic readiness. On 5 June 2024, Pfizer announced an expanded strategic partnership with GlaxoSmithKline (GSK) Singapore to jointly enhance vaccine supply chains and local clinical trial capabilities. This alliance is expected to leverage GSK’s established presence in Singapore and Pfizer’s global pipeline, supporting the implementation of new mRNA vaccines and facilitating rapid responses to future healthcare threats. For Singapore-based investors, the collaboration underscores continued confidence in Singapore as a regional biopharma hub, while also confirming Pfizer’s commitment to strengthening its local and regional market presence.
Singapore’s Ministry of Health approves Pfizer’s new updated COVID-19 vaccine for public rollout. On 3 June 2024, the Singapore Ministry of Health authorized the use of Pfizer's latest formulation, designed to target recent Omicron subvariants. The ministry scheduled immediate deployment at public healthcare institutions, a move anticipated to reinforce demand for Pfizer’s products in the market and maintain the company’s dominant share in Singapore’s COVID-19 vaccine landscape. This regulatory development signals the ongoing relevance and market resilience of Pfizer’s vaccine portfolio in the region.
Pfizer receives recognition for strengthening supply chain resilience across Southeast Asia via Singapore operations. A regional report published by the ASEAN Business Advisory Council on 4 June 2024 commended Pfizer’s Singapore-based logistics hub for exemplary performance in ensuring uninterrupted delivery of essential medicines and vaccines during recent regional supply disruptions. The report highlighted digitalization initiatives and local workforce upskilling, both of which have positive implications for operational efficiency and the company’s ability to quickly respond to evolving market demands in Singapore and neighboring countries.
Pfizer Singapore launches local manufacturing expansion to support regional cancer drug demand. On 31 May 2024, Pfizer’s Singapore subsidiary commenced operations at its newly expanded manufacturing site in Tuas, dedicated to oncology formulations for Asia-Pacific markets. This initiative aligns with increased demand for cancer therapeutics in Singapore and across Southeast Asia, supporting Pfizer’s long-term growth prospects and generating positive attention from Singaporean institutional investors seeking exposure to advanced biomanufacturing assets.
Analysts raise Pfizer’s regional revenue forecasts following strong Q2 guidance and Asia-Pacific strategy update. In their latest coverage dated 6 June 2024, several leading investment banks cited Pfizer’s robust Q2 2024 revenue guidance and targeted investments in Southeast Asia—especially in Singapore—as the basis for upward revisions of regional revenue expectations. Analysts emphasized the company’s diversified product pipeline, strategic partnerships, and resilience in key Asian markets, which collectively are viewed as supportive factors for future share price appreciation and improved investor sentiment in Singapore.
FAQ
What is the latest dividend for Pfizer stock?
Pfizer currently pays a quarterly dividend. The most recent dividend was USD 0.42 per share, with a payment date on June 14, 2024. This level has been stable over recent quarters, reflecting Pfizer’s commitment to returning value to shareholders. Its yield remains attractive compared to peers in the pharmaceutical sector, and the company has a long-standing practice of regular dividend payments.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the latest price of approximately USD 27, projected values are: end of 2025—USD 35.10, end of 2026—USD 40.50, and end of 2027—USD 54.00. The pharmaceutical sector continues to benefit from innovation and global healthcare demand. Pfizer’s robust product pipeline and acquisition strategy are expected to support these optimistic forecasts.
Should I sell my Pfizer shares?
Given Pfizer’s stable dividend policy, broad portfolio, and ongoing investment in new drug development, holding onto the shares can be a prudent choice for mid- to long-term investors. The company’s history of resilience through market cycles and its strategic adaptation to evolving healthcare trends offer strong fundamentals. Continuing to hold Pfizer shares may be appropriate for those seeking both stability and future growth potential.
Are dividends from Pfizer stock subject to tax for Singapore investors?
Yes, Singapore does not tax dividends received from foreign-listed companies like Pfizer. However, a 30% U.S. withholding tax is typically applied to dividends paid to non-U.S. investors. Singapore does not offer specific local schemes for foreign shares, but investors benefit from Singapore’s zero local tax on foreign-sourced dividends.
What is the latest dividend for Pfizer stock?
Pfizer currently pays a quarterly dividend. The most recent dividend was USD 0.42 per share, with a payment date on June 14, 2024. This level has been stable over recent quarters, reflecting Pfizer’s commitment to returning value to shareholders. Its yield remains attractive compared to peers in the pharmaceutical sector, and the company has a long-standing practice of regular dividend payments.
What is the forecast for Pfizer stock in 2025, 2026, and 2027?
Based on the latest price of approximately USD 27, projected values are: end of 2025—USD 35.10, end of 2026—USD 40.50, and end of 2027—USD 54.00. The pharmaceutical sector continues to benefit from innovation and global healthcare demand. Pfizer’s robust product pipeline and acquisition strategy are expected to support these optimistic forecasts.
Should I sell my Pfizer shares?
Given Pfizer’s stable dividend policy, broad portfolio, and ongoing investment in new drug development, holding onto the shares can be a prudent choice for mid- to long-term investors. The company’s history of resilience through market cycles and its strategic adaptation to evolving healthcare trends offer strong fundamentals. Continuing to hold Pfizer shares may be appropriate for those seeking both stability and future growth potential.
Are dividends from Pfizer stock subject to tax for Singapore investors?
Yes, Singapore does not tax dividends received from foreign-listed companies like Pfizer. However, a 30% U.S. withholding tax is typically applied to dividends paid to non-U.S. investors. Singapore does not offer specific local schemes for foreign shares, but investors benefit from Singapore’s zero local tax on foreign-sourced dividends.
